<DOC>
	<DOCNO>NCT02384369</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study SNC-102 adult subject cPTSD , add pre-existing treatment include prazosin without psychotropic drug . Subjects treat SNC-102 tablet match placebo BID basis 8 week . Subjects evaluate symptoms combat-related posttraumatic stress disorder ( cPTSD ) measure Clinician Administered PTSD Scale ( CAPS-5 ) , compare response placebo .</brief_summary>
	<brief_title>Trial Oral SNC-102 Subjects With Combat-Related Posttraumatic Stress Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Combat Disorders</mesh_term>
	<criteria>Confirmation diagnosis BoardCertified psychiatrist combatrelated posttraumatic stress disorder ( cPTSD ) accord Diagnostic Statistical Manual ( DSM5 ) criteria PTSD history link symptom combat exposure . Taking prazosin treatment cPTSD minimum 4 week , stable dose least 2 week , expect remain dose duration study . Having sufficient residual symptom PTSD current drug regimen , opinion Principal Investigator , additional treatment disorder clinically indicate . Body mass index 1838 kg/m2 inclusive . Plans initiate new psychotropic medication ( study drug ) period study . Plans change dose discontinue prazosin psychotropic medication period study . Diagnosis epilepsy treatment antiepileptic drug . Use alcohol cannabis extent , view Principal Investigator , raise significant risk medication noncompliance , drink alcohol midnight day study visit miss study visit . Any use nonprescribed opiate , cocaine , street drug cannabis month prior study entry . Any history major medical complication alcohol use include alcoholic hepatitis , cirrhosis liver , pancreatitis , alcohol withdrawal seizure , delirium tremens . Patients take moderate , stable dos oral opiate chronic pain may admit discretion Principal Investigator . Current use drug prazosin significant alphaadrenergic blocking effect , associate symptomatic orthostatic hypotension . Current use cocaine , amphetamine , phencyclidine , ketamine , document either history urinary drug screen Screening Baseline Visits . Urinary drug screen ketamine phencyclidine conduct offsite Study Sponsor urinary drug screen available study site include drug . Any drug identify incidentally drug screen warrant exclusion Principal Investigator , consultation Sponsor , judge presence could interfere objective trial . Pregnant lactate female . Women childbearing potential , unless subject agrees use dual contraceptive method study drug 1 month afterward , , opinion Principal Investigator , effective adequate subject 's circumstance . Any severe , acute , chronic medical psychiatric condition , laboratory abnormality could increase risk associate study participation study drug administration , could interfere informed consent process and/or compliance requirement study , could interfere interpretation study result , Principal Investigator 's opinion , would make subject inappropriate entry study . Use nonpharmacologic psychiatric somatic treatment within 4 week baseline , expect course study . Such treatment include limited electroconvulsive therapy , transcranial magnetic stimulation , transcranial direct current stimulation , vagus nerve stimulation , light therapy , acupuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>